Get the Stockscreener App
1.67
8.74%
-0.16
After Hours:
1.68
0.01
+0.60%
Erasca Inc stock is traded at $1.67, with a volume of 1.61M.
It is down -8.74% in the last 24 hours and down -37.45% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.83
Open:
$1.83
24h Volume:
1.61M
Relative Volume:
1.16
Market Cap:
$472.15M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-2.0366
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-11.17%
1M Performance:
-37.45%
6M Performance:
-34.25%
1Y Performance:
-4.02%
1-Day Range:
$1.66
$1.85
1-Week Range:
$1.66
$2.025
52-Week Range:
$1.66
$3.45
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.67 | 472.15M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex
Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News
Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat
Erasca (NASDAQ:ERAS) Stock Price Down 6.1%Time to Sell? - MarketBeat
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha
Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround - MSN
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Stock Price Down 6.2%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Sells 13,100 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by Barclays PLC - Defense World
Erasca Highlights Strategic Focus at Healthcare Conference - TipRanks
Jane Street Group LLC Trims Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Down 8.7%What's Next? - MarketBeat
Erasca (NASDAQ:ERAS) Upgraded at Bank of America - Defense World
Erasca (NASDAQ:ERAS) Shares Up 3%Still a Buy? - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Principal Financial Group Inc. - Defense World
Erasca (NASDAQ:ERAS) Rating Increased to Buy at Bank of America - MarketBeat
Erasca (NASDAQ:ERAS) Shares Gap UpWhat's Next? - MarketBeat
Erasca to Present at J.P. Morgan Healthcare Conference 2025: RAS/MAPK Cancer Innovations - StockTitan
Franklin Resources Inc. Invests $181,000 in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Up 7.6%Should You Buy? - MarketBeat
Geode Capital Management LLC Raises Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Geode Capital Management LLC Has $12.30 Million Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Barclays PLC Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
State Street Corp Acquires 3,569,440 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Purchased by State Street Corp - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $994,000 in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Fmr LLC Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
The Manufacturers Life Insurance Company Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Charles Schwab Investment Management Inc. Purchases 390,209 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Stock Position Raised by Charles Schwab Investment Management Inc. - MarketBeat
Clear Street starts Erasca with Buy, sets $5 price target By Investing.com - Investing.com UK
Clear Street starts Erasca with Buy, sets $5 price target - Investing.com
Erasca, Inc. (NASDAQ:ERAS) Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
One Erasca Insider Raised Stake By 14% In Previous Year - Simply Wall St
Janus Henderson Group PLC Has $11.20 Million Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Walleye Capital LLC Has $2.59 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):